Back to Search Start Over

Apixaban (Eliquis)-Induced Rash: A Case Report.

Authors :
Nadella H
Vilar N
Nochimson R
Source :
Cureus [Cureus] 2023 Dec 10; Vol. 15 (12), pp. e50273. Date of Electronic Publication: 2023 Dec 10 (Print Publication: 2023).
Publication Year :
2023

Abstract

Many anticoagulants are indicated as prophylaxis and treatment for conditions that may lead to thromboembolisms or atrial fibrillation. Among those, apixaban, a reversible direct inhibitor of factor Xa, is one of the most popular. Apixaban is known to cause a variety of side effects; however, for this paper, the focus is on hypersensitivity reactions. Although several cases will be referenced from the literature, we present a case with a history of a dermatological disease before the use of a direct oral anticoagulant. A 74-year-old female patient with a history of pemphigus vulgaris and a diagnosis of pulmonary embolism and right distal vein thrombosis managed with apixaban presented with a pruritic coalescent erythematous dermatitis throughout her torso, back, and lower extremities three days post-apixaban treatment. In accordance with her physical examination, the apixaban regimen was withdrawn, and oral dabigatran, a direct thrombin inhibitor, was initiated. At the patient's five-day follow-up, clinical improvement was noted. Through clinical diagnosis, it is believed that this dermatitis was a reaction to the apixaban treatment course.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright © 2023, Nadella et al.)

Details

Language :
English
ISSN :
2168-8184
Volume :
15
Issue :
12
Database :
MEDLINE
Journal :
Cureus
Publication Type :
Report
Accession number :
38196431
Full Text :
https://doi.org/10.7759/cureus.50273